Form D · Biotechnology

Shoreline Biosciences, Inc.

San Diego, CA · CIK 0001818870

Offering snapshot reported Nov 9, 2021 · SEC filing

Reported sold
$140M
Offering amount: $140M
Investors reported
25
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 28, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 9, 2021Initial$140,000,104No comparison25SEC filing
Feb 16, 2021Initial$43,000,002No comparison20SEC filing
Jul 22, 2020Initial$3,000,000No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$2.77M
Finders' fees
$0
Form D file number
021-420540

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Wedbush Securities Inc.877

Source: Form D, filed Nov 9, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Scott Forrest Executive
Marios Fotiadis Director
Christopher Fuglesang Director
Steven Holtzman Director
Vanessa Jacoby Executive
Dan S. Kaufman Director
Kimberly Manhard Director
William Sandborn Executive
Kleanthis G. Xanthopoulos Director, Executive
Kleanthis G. Xanthopoulos, Ph.D. Director, Executive
Fan Yu Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
11408 Sorrento Valley Road
San Diego, CA, 92121